NASDAQ:VYNT - Vyant Bio Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.08
▼ -0.08 (-2.53%)

This chart shows the closing price for VYNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vyant Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYNT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Vyant Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.08.

This chart shows the closing price for VYNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Vyant Bio. This rating has held steady since November 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2018Maxim GroupReiterated RatingHoldHigh
9/19/2018HC WainwrightSet Price TargetBuy$3.00Low
8/15/2018HC WainwrightSet Price TargetBuy$3.00High
8/14/2018Maxim GroupReiterated RatingHoldHigh
5/29/2018HC WainwrightSet Price TargetBuy$3.00Low
4/6/2018Dawson JamesDowngradeBuy ➝ NeutralHigh
4/3/2018Maxim GroupDowngradeBuy ➝ Hold$6.00Low
2/6/2018HC WainwrightSet Price TargetBuy$6.00Low
1/16/2018HC WainwrightSet Price TargetBuy$6.00High
12/13/2017Maxim GroupSet Price TargetBuy$6.00Medium
12/7/2017Maxim GroupInitiated CoverageBuy ➝ Buy$6.00High
11/29/2017HC WainwrightSet Price TargetBuy$6.00High
9/21/2017HC WainwrightReiterated RatingBuy$6.00Medium
8/15/2017HC WainwrightSet Price TargetBuy$6.00High
6/27/2017Dawson JamesInitiated CoverageBuyHigh
6/26/2017BenchmarkInitiated CoverageSpeculative Buy$3.85 ➝ $6.00High
3/27/2017HC WainwrightReiterated RatingBuy$6.00High
9/27/2016HC WainwrightInitiated CoverageBuy$6.00N/A
9/26/2016Rodman & RenshawInitiated CoverageBuy$6.00N/A
(Data available from 7/23/2016 forward)
Vyant Bio logo
Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.
Read More

Today's Range

Now: $3.08
Low: $3.02
High: $3.17

50 Day Range

MA: $3.62
Low: $3.02
High: $4.05

52 Week Range

Now: $3.08
Low: $2.11
High: $17.50

Volume

52,646 shs

Average Volume

1,401,813 shs

Market Capitalization

$89.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Vyant Bio?

The following sell-side analysts have issued stock ratings on Vyant Bio in the last year:
View the latest analyst ratings for VYNT.

What is the current price target for Vyant Bio?

0 Wall Street analysts have set twelve-month price targets for Vyant Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Vyant Bio in the next year.
View the latest price targets for VYNT.

What is the current consensus analyst rating for Vyant Bio?

Vyant Bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VYNT.

What other companies compete with Vyant Bio?

How do I contact Vyant Bio's investor relations team?

Vyant Bio's physical mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The company's listed phone number is 201 479 1357 and its investor relations email address is [email protected] The official website for Vyant Bio is stemonix.com.